ISSN: 2148-8274 / E-ISSN: 2587-0084
, Türk Üreme Tıbbı ve Cerrahisi
Dergisi

Turkish Journal of Reproductive Medicine and Surgery

Dernek Sitesi
Kayıtlı İndexler
ORİJİNAL ARAŞTIRMALAR
Polikistik Over Sendromlu Hastalarda Memede Fibrokistik Hastalığın Ultrasonografi İle Değerlendirilmesi
Ultrasonographic Evaluation of Fibrocystic Breast Disease in Patients with Polycystic Ovary Syndrome
Received Date : 14 Nov 2023
Accepted Date : 27 Dec 2023
Available Online : 29 Dec 2023
Özet PDF Benzer Makaleler
Nura Fitnat TOPBAŞ SELÇUKİa, Eda ÜREYEN ÖZDEMİRb, Kübra BAĞCIc, Meric KABAKCIa, Nail UZUNLULUd, Pınar YALÇIN BAHATe
aDepartment of Obstetrics and Gynecology, University of Health Sciences Turkey, İstanbul Şisli Hamidiye Etfal Training and Research Hospital, İstanbul, Türkiye bDepartment of Obstetrics and Gynecology, Ankara City Hospital, Ankara, Türkiye cDepartment of Obstetrics and Gynecology, Yeni Yüzyıl University Gaziosmanpasa Hospital, İstanbul, Türkiye dDepartment of Radiology, Private Ikitelli BHT Clinic Hospital, İstanbul, Türkiye eDepartment of Obstetrics and Gynecology, University of Health Sciences Turkey, İstanbul Kanuni Sultan Süleyman Training and Research Hospital, İstanbul, Türkiye
Doi: 10.24074/tjrms.2023-100320 - Makale Dili: EN
Turkish Journal of Reproductive Medicine and Surgery. 2024;8(2):48-53.
ÖZET
Amaç: Polikistik over sendromlu (PKOS) hastaların meme ultrasonu ile fibrokistik meme hastalığı varlığı açısından değerlendirerek PKOS’un iyi huylu meme hastalığı için artmış risk oluşturup oluşturmadığını değerlendirmek. Gereç ve Yöntemler: Bu prospektif vaka kontrollü çalışma üçüncü basamak bir merkezde gerçekleştirildi. Çalışma grubunu Rotterdam kriterlerine göre PKOS tanısı alan 41 hastadan oluşturdu. Kontrol grubuna bilinen herhangi bir hastalığı olmayan çalışma grubu ile benzer yaş grubunda 41 hasta dahil edildi. Tüm hastalara ultrason ile meme muayenesi yapıldı ve bulgular BI-RADS'a göre sınıflandırıldı. Bulgular: Çalışma grubundaki hastalar kontrol grubundaki hastalara kıyasla anlamlı derecede yüksek oranda BI-RADS 2 ve 3 olarak kategorize edildi; sırasıyla %26,8'e karşı %9,8, %9,8'e karşı %2,4 (p < 0,001). Her iki gruptaki hastaların çoğunluğu BI-RADS 1 olarak sınıflandırıldı ve her iki grupta da herhangi bir malignite veya malignite şüphesi bildirilmedi. Ayrıca gruplar arasında parenkim paterni açısından da anlamlı fark gözlendi (p=0,02). Kontrol grubunun %36,6'sında herhangi bir parenkim değişikliği gözlenmezken, bu sayı çalışma grubunda %17,1 idi. Kontrol grubuyla (%2,4) karşılaştırıldığında PKOS'lu hastaların önemli bir kısmında fibrokistik meme hastalığı (%14,6) izlendi. Sonuç: Bu çalışmada PKOS ile fibrokistik meme hastalığı arasındaki ilişki değerlendirilmiş ve PKOS'lu hastalarda fibrokistik meme hastalığı riskinin daha yüksek olduğu bulunmuştur. PKOS'lu hastaların ultrasonografi ile rutin meme değerlendirmesi, fibrokistik meme hastalığının saptanması ve bu hastaların uzun süreli yönetimi açısından önemlidir.
Anahtar Kelimeler: Polikistik over sendromu; fibrokistik meme hastalığı; ultrasonografi, meme ile ilgili
ABSTRACT
Objective: To evaluate whether polycystic ovary syndrome (PCOS) constitutes an increased risk for benign breast disease by assessing PCOS patients in terms of the presence of fibrocystic breast disease with breast ultrasound assessment. Materials and Methods: This prospective case-controlled study was conducted at a tertiary referral center. Study group consisted of 41 patients who were diagnosed with PCOS according to the Rotterdam criteria. Control group included 41 age-matched patients without any known diseases. All patients received a breast examination with ultrasound and findings were categorized according to BI-RADS. Results: A significantly higher percentage of patients in the study group were categorized as BI-RADS 2 and 3 in comparison to the patients in the control group; 26.8% vs. 9.8%, 9.8% vs. 2.4%, respectively (p < 0.001). Majority of patients in both groups were categorized as BI-RADS 1 and no malignancy or a suspicion of malignancy was reported in both groups. Additionally, a significant difference was observed between the groups in terms of parenchymal pattern (p = 0.02). No parenchymal change was observed in 36.6% of the control group whereas this number was 17.1% in the study group. A significantly higher number of patients with PCOS had fibrocystic breast disease (14.6%) when compared to the control group (2.4%). Conclusion: This study evaluated the association between PCOS and fibrocystic breast disease and the risk of fibrocystic breast disease was found to be higher in patients with PCOS. A routine breast evaluation of PCOS patients with ultrasonography is important for detection of fibrocystic breast disease and for long-term management of these patients.
Keywords: Polycystic ovary syndrome; fibrocystic breast disease; ultrasonography mammary
REFERANSLAR
  1. Gadducci A, Gargini A, Palla E, Fanucchi A, Genazzani AR. Polycystic ovary syndrome and gynecological cancers: is there a link? Gynecol Endocrinol. 2005;20(4):200-8. [Crossref]  [PubMed] 
  2. Solomon CG. The epidemiology of polycystic ovary syndrome. Prevalence and associated disease risks. Endocrinol Metab Clin North Am. 1999;28(2):247-63. [Crossref]  [PubMed] 
  3. Lobo RA, Carmina E. The importance of diagnosing the polycystic ovary syndrome. Ann Intern Med. 2000;132(12):989-93. [Crossref]  [PubMed] 
  4. Bozdag G, Mumusoglu S, Zengin D, Karabulut E, Yildiz BO. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod. 2016;31(12):2841-55. [Crossref]  [PubMed] 
  5. March WA, Moore VM, Willson KJ, Phillips DIW, Norman RJ, Davies MJ. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod. 2010;25(2):544-51. [Crossref]  [PubMed] 
  6. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev. 1997;18(6):774-800. [Crossref]  [PubMed] 
  7. Goodman NF, Cobin RH, Futterweit W, Glueck JS, Legro RS, Carmina E, et al. American Association Of Clinical Endocrinologists, American College Of Endocrinology, And Androgen Excess And Pcos Society Disease State Clinical Review: Guide To The Best Practices In The Evaluation And Treatment Of Polycystic Ovary Syndrome--Part 1. Endocr Pract. 2015;21(11):1291-300. [Crossref]  [PubMed] 
  8. Legro RS, Gnatuk CL, Kunselman AR, Dunaif A. Changes in glucose tolerance over time in women with polycystic ovary syndrome: a controlled study. J Clin Endocrinol Metab. 2005;90(6):3236-42. [Crossref]  [PubMed] 
  9. Bremer AA, Miller WL. The serine phosphorylation hypothesis of polycystic ovary syndrome: a unifying mechanism for hyperandrogenemia and insulin resistance. Fertil Steril. 2008;89(5):1039-48. [Crossref]  [PubMed] 
  10. Mukherjee S, Maitra A. Molecular & genetic factors contributing to insulin resistance in polycystic ovary syndrome. Indian J Med Res. 2010;131:743-60.
  11. Barbieri RL, Makris A, Ryan KJ. Insulin stimulates androgen accumulation in incubations of human ovarian stroma and theca. Obstet Gynecol. 1984;64(3 Suppl):73S-80S. [Crossref]  [PubMed] 
  12. Daniilidis A, Dinas K. Long term health consequences of polycystic ovarian syndrome: a review analysis. Hippokratia. 2009;13(2):90-2.
  13. Palomba S, Santagni S, Falbo A, La Sala GB. Complications and challenges associated with polycystic ovary syndrome: current perspectives. Int J Womens Health. 2015;7:745-63. [Crossref]  [PubMed]  [PMC] 
  14. Wild RA, Carmina E, Diamanti-Kandarakis E, Dokras A, Escobar-Morreale HF, Futterweit W, et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J Clin Endocrinol Metab. 2010;95(5):2038-49. [Crossref]  [PubMed] 
  15. Xavier LB, Sóter MO, Sales MF, Oliveira DK, Reis HJ, Candido AL, et al. Evaluation of PCSK9 levels and its genetic polymorphisms in women with polycystic ovary syndrome. Gene. 2018;644:129-36. [Crossref]  [PubMed] 
  16. Trivax B, Azziz R. Diagnosis of polycystic ovary syndrome. Clin Obstet Gynecol. 2007;50(1):168-77. [Crossref]  [PubMed] 
  17. Harris HR, Terry KL. Polycystic ovary syndrome and risk of endometrial, ovarian, and breast cancer: a systematic review. Fertil Res Pract. 2016;2:14. [Crossref]  [PubMed]  [PMC] 
  18. Barry JA, Azizia MM, Hardiman PJ. Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2014;20(5):748-58. [Crossref]  [PubMed]  [PMC] 
  19. Cowan LD, Gordis L, Tonascia JA, Jones GS. Breast cancer incidence in women with a history of progesterone deficiency. Am J Epidemiol. 1981;114 (2):209-17. [Crossref]  [PubMed] 
  20. El-Bastawissi AY, White E, Mandelson MT, Taplin SH. Reproductive and hormonal factors associated with mammographic breast density by age (United States). Cancer Causes Control. 2000;11(10):955-63. [Crossref]  [PubMed] 
  21. Soran A, Talbott EO, Zborowski JV, Wilson JW. The prevalence of benign breast disease in women with polycystic ovary syndrome: a review of a 12-year follow-up. Int J Clin Pract. 2005;59(7):795-7. [Crossref]  [PubMed] 
  22. Gumus II, Koktener A, Dogan D, Turhan NO. Polycystic ovary syndrome and fibrocystic breast disease: is there any association? Arch Gynecol Obstet. 2009;280(2):249-53. [Crossref]  [PubMed] 
  23. Saraç Z, Bilgen I. Association between Insulin Resistance and Breast Parenchyma in Women with Polycystic Ovary Syndrome. Turkish Journal of Endocrinology and Metabolism. 2012;16:1-5.
  24. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81(1):19-25. [Crossref] 
  25. Mercado CL. BI-RADS update. Radiol Clin North Am. 2014;52(3):481-7. [Crossref]  [PubMed] 
  26. D'Orsi C, Sickles E, Mendelson E, Morris E. ACR BI-RADS atlas, breast imaging reporting and data system. American College of Radiology. 2013;
  27. Atiomo WU, El-Mahdi E, Hardiman P. Familial associations in women with polycystic ovary syndrome. Fertil Steril. 2003;80(1):143-5. [Crossref]  [PubMed] 
  28. Baron JA, Weiderpass E, Newcomb PA, Stampfer M, Titus-Ernstoff L, Egan KM, et al. Metabolic disorders and breast cancer risk (United States). Cancer Causes Control. 2001;12(10):875-80. [Crossref]  [PubMed] 
  29. Lundberg FE, Iliadou AN, Rodriguez-Wallberg K, Gemzell-Danielsson K, Johansson ALV. The risk of breast and gynecological cancer in women with a diagnosis of infertility: a nationwide population-based study. Eur J Epidemiol. 2019;34(5):499-507. [Crossref]  [PubMed]  [PMC] 
  30. Dogliotti L, Orlandi F, Angeli A. The endocrine basis of benign breast disorders. World J Surg. 1989;13(6):674-9. [Crossref]  [PubMed] 
  31. Ng EH, Ji CY, Tan PH, Lin V, Soo KC, Lee KO. Altered serum levels of insulin-like growth-factor binding proteins in breast cancer patients. Ann Surg Oncol. 1998;5(2):194-201. [Crossref]  [PubMed] 
  32. Torrisi R, Parodi S, Fontana V, Pensa F, Casella C, Barreca A, et al. Effect of fenretinide on plasma IGF-I and IGFBP-3 in early breast cancer patients. Int J Cancer. 1998;76(6):787-90. [Crossref] 
  33. Malherbe K, Khan M, Fatima S. Fibrocystic Breast Disease. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 [cited 2021 Sep 26]. Available from: [Link] 
  34. Carvalho MJ, Subtil S, Rodrigues Â, Oliveira J, Figueiredo-Dias M. Controversial association between polycystic ovary syndrome and breast cancer. Eur J Obstet Gynecol Reprod Biol. 2019;243:125-32. [Crossref]  [PubMed] 
  35. Anderson KE, Sellers TA, Chen PL, Rich SS, Hong CP, Folsom AR. Association of Stein-Leventhal syndrome with the incidence of postmenopausal breast carcinoma in a large prospective study of women in Iowa. Cancer. 1997;79(3):494-9. [Crossref] 
  36. D'Amelio R, Farris M, Grande S, Feraudo E, Iuliano A. [Incidence of fibrocystic disease of the breast in women with polycystic ovary. Clinico-instrumental study]. Minerva Ginecol. 2000;52(9):321-5.
  37. Panaritis V, Despotidis P, Kyriakidis A. Diameter of mammary terminal ducts as an additional tool in evaluation of women with polycystic ovarium disease. Arch Gynecol Obstet. 2004;270(4):252-4. [Crossref]  [PubMed] 
  38. Ozkaya E, Cakir E, Cinar M, Kara F, Baser E, Cakir C, et al. Is hyperandrogenemia protective for fibrocystic breast disease in PCOS? Gynecol Endocrinol. 2012;28(6):468-71. [Crossref]  [PubMed] 
  39. Talaei A, Moradi A, Rafiei F. The evaluation of the effect of metformin on breast fibrocystic disease. Breast Dis. 2017;37(2):49-53. [Crossref]  [PubMed] 
Copyright © 2024
Bu sitenin tüm hakları Üreme Tıbbı ve Cerrahisi Derneği'ne aittir.
Site Tasarım ve Yönetim: Türkiye Klinikleri